Compare GEO & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEO | MESO |
|---|---|---|
| Founded | 1984 | 2004 |
| Country | United States | Australia |
| Employees | N/A | 81 |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 1996 | N/A |
| Metric | GEO | MESO |
|---|---|---|
| Price | $16.80 | $14.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $39.67 | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 315.8K |
| Earning Date | 05-06-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 727.27 | N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | ★ $2,263,420,000.00 | N/A |
| Revenue This Year | $13.74 | $644.56 |
| Revenue Next Year | $9.99 | $38.70 |
| P/E Ratio | $9.51 | ★ N/A |
| Revenue Growth | ★ 3.85 | N/A |
| 52 Week Low | $12.51 | $9.61 |
| 52 Week High | $32.09 | $21.50 |
| Indicator | GEO | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 59.06 | 40.95 |
| Support Level | $16.52 | $13.45 |
| Resistance Level | $17.64 | $16.33 |
| Average True Range (ATR) | 0.71 | 0.50 |
| MACD | 0.25 | 0.06 |
| Stochastic Oscillator | 78.05 | 13.93 |
The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.